Congress hold a conference on a EpiPen cost hikes Wednesday, Sept. 21. Here are 5 takeaways from a hearing.
Congress heaped ridicule on a CEO of a drug association that creates a EpiPen diagnosis during a cabinet assembly Wednesday.
Here’s what we schooled from Mylan (MYL) CEO Heather Bresch’s testimony and doubt before a House Oversight panel.
1. Solutions are in brief supply.
Well, this shouldn’t warn you. But hearings like this move it into full view. The conference was complicated on rhetoric, light on answers.
After Mylan lifted a base price of an EpiPen two-pack from $100 in 2009 to some-more than $600 in 2016, consumers lambasted a association as a latest instance of a miserly curative hulk holding advantage of infirm Americans.
Congress assimilated a parade. Rep. Stephen Lynch, D-Mass., called it “disgraceful” and “disgusting,” while Rep. Elijah Cummings, D-Maryland, bloody Mylan for seeking “to get dirty abounding during a responsibility of a constituents.”
Lectures were plentiful. Agreement on what to do about it? Not so much.
Lynch pronounced a conditions illustrates that Medicare needs a energy to negotiate drug prices, that some experts have pronounced could help, though there was no concrete contention of a matter. Others have suggested that a U.S. needs to exercise cost controls on life-saving drugs. That idea, too, was nowhere to be found.
2. Mylan isn’t sorry.
Bresch didn’t behind down. She blamed a “complexity” of a health-care complement for creation it seem like Mylan reaps outrageous boost on EpiPen.
“I truly trust the story got forward of a facts,” she said, adding that Mylan creates a distinction of $100 per two-pack.
Still, experts contend that’s a poignant distinction margin, generally deliberation that a treatment has hardly altered for decades.
3. Heather Bresch thinks her remuneration is normal for her industry.
The Mylan CEO received about $18.9 million in sum remuneration in 2015, that she was forced to acknowledge during a hearing.
“Sounds like you’re doing flattering good on this,” Rep. John Mica, R-Florida, said. “How does your remuneration examination to peers in a industry?”
“It’s in a middle,” Bresch replied.
That’s generally accurate for 2015, according to a new USA TODAY examination of SP Global Market Intelligence data.
But for a final 5 years, Mylan had a second-highest executive remuneration in a whole drug industry, according to a Wall Street Journal.
4. A plan is rising for price-hiking drug companies.
Roll with a punches. That’s a proceed drug companies seem to be taking.
Rep. Elijah Cummings, D-Maryland, compared it to Muhammad Ali’s “rope-a-dope” strategy.
After holding a few punches, a companies “keep on lifting their prices,” Cummings said.
Why? Because, Cummings said, zero changes. He forked to identical examples during “pharma bro” Martin Shkreli’s former company, Turing Pharmaceuticals , and argumentative organisation Valeant Pharmaceuticals (VRX).
Shkreli dumbfounded politicos by observant after he refused to attest to a same cabinet progressing this year that a row was done adult of “imbeciles.”
5. An EpiPen with longer shelf life might be coming.
Bresch pronounced Mylan “within days” will contention a ask to a Food and Drug Administration for examination of an EpiPen with longer shelf life. The stream chronicle expires in 18 months, she said. The idea for a new chronicle is 24 months.
Follow USA TODAY contributor Nathan Bomey on Twitter @NathanBomey.
MYLAN EPIPEN CONTROVERSYMylan CEO: ‘Misconception’ about EpiPen boost | 0:46
The CEO of Mylan responded to a new Epipen debate Wednesday, Sept. 21.
MYLAN EPIPEN CONTROVERSYLawmaker says Mylan’s lobbying non-stop a doorway for EpiPen inspection | 1:01
“You’ve been in these hallways to ask us to make people buy your stuff,” U.S. Rep. Mick Mulvaney said.
Video supposing by Newsy
MYLAN EPIPEN CONTROVERSYEpiPen sales boost due to CEO’s mother’s position in preparation organisation | 2:34
Gayle Manchin, mom of Mylan CEO Heather Bresch, helped boost sales of a EpiPen in her position as boss of a National Association of State Boards of Education.
MYLAN EPIPEN CONTROVERSY5 EpiPen execs raked in roughly $300 million after outrageous cost hikes | 0:38
It wasn’t usually a CEO of Mylan, Heather Bresch, who got a outrageous compensate lift after a large EpiPen cost travel scandal. Jose Sepulveda (@josesepulveda87) has more.
MYLAN EPIPEN CONTROVERSYProtesters broach petitions over EpiPen pricing | 1:05
Protesters collected in Cecil Township, Pennsylvania Tuesday to broach petitions from hundreds of thousands of consumers and allergy sufferers job for Mylan to revoke a cost of EpiPens. (Aug. 30)
MYLAN EPIPEN CONTROVERSYMylan offers general EpiPen: What’s a difference? | 0:42
Mylan offers general EpiPen: What’s a difference?
MYLAN EPIPEN CONTROVERSYMylan cuts studious cost of EpiPen | 1:13
Pharmaceutical association Mylan has pronounced it will revoke a studious cost of a serious allergy diagnosis drug EpiPen.
MYLAN EPIPEN CONTROVERSYSarah Jessica Parker cuts ties with EpiPen | 0:37
Joining scores of people angry over a cost travel of a EpiPen, Sarah Jessica Parker will no longer be compared with a drugmaker who manufactures it.
MYLAN EPIPEN CONTROVERSYEpiPen builder offers discounts after cost travel | 0:41
The debate over a cost of a EpiPen has reached a heat representation as prices have risen by some-more than 400%, costing adult to $600 for dual of a pens.
MYLAN EPIPEN CONTROVERSYMylan not a usually drugmaker with large distinction margins | 0:37
Mylan is sketch glow for flitting off large cost hikes for a EpiPen allergy treatment. But it’s distant from being a drug association with a many pricing power.
MYLAN EPIPEN CONTROVERSYEpiPen drug association Mylan and CEO underneath inspection after cost boost | 1:28
Mylan Pharmaceuticals’ CEO had a medium bottom income in 2015, though her sum remuneration was in a multimillions.
Video supposing by Newsy
MYLAN EPIPEN CONTROVERSYCongress final answers over EpiPen astronomical cost travel | 0:45
The Senate Judiciary Committee is looking during a pointy cost increases for EpiPens.